Erdafitinib
Balversa · FGFR inhibitor
Hyperphosphatemia is an on-target class effect.
Lytgobi · Futi
FGFR inhibitor · approved 2022 · 6 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
An irreversible FGFR1-4 inhibitor — same on-target hyperphosphatemia signature as the class.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Hyperphosphatemia is the most common adverse event, reported in ~85% of patients (any grade, most low-grade) in the pivotal FOENIX-CCA2 trial; it is on-target, dose-related, and confirmed as a pharmacodynamic effect in first-in-human work.Source: Goyal et al., N Engl J Med 2023
Early — within the first cycles.
Distilled from: “Early — within the first cycles.”
This agent's defining kidney lesion — its #1 signature. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Renal electrolyte derangement — magnesium/potassium/calcium wasting (cisplatin, anti-EGFR antibodies) or retention (FGFR-inhibitor hyperphosphatemia, tumor-lysis hyperkalemia/hyperphosphatemia).
Irreversible (covalent) pan-FGFR1-4 inhibitor; approved for FGFR2-fusion/rearrangement-positive intrahepatic cholangiocarcinoma.
Proximal Tubule
Bulk reabsorption + drug uptake (OCT2, OATs)
Class-level context for the major non-renal toxicities of the FGFR inhibitor class.
Ophthalmic
Keratopathy, uveitis, retinopathy
Dermatologic
Rash, HFS, SJS/TEN, vitiligo
6 primary references — trials, cohorts, mechanism, and reviews. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Everything below is FAERS — adverse events someone chose to report, about 222 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
Reported with a death outcome
42 of 222 reports
Reported with hospitalization
71 of 222 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Futibatinib sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Balversa · FGFR inhibitor
Hyperphosphatemia is an on-target class effect.
Pemazyre · FGFR inhibitor
Hyperphosphatemia; nephrocalcinosis risk.
Truseltiq · FGFR inhibitor
Hyperphosphatemia — on-target FGFR class effect; nephrocalcinosis risk.
Xgeva · Anti-RANKL antibody
Severe hypocalcemia in low GFR; not directly nephrotoxic.
Portrazza · Anti-EGFR antibody
Severe hypomagnesemia, class effect.
Aqupla · Platinum agent
Second-gen platinum with reduced renal toxicity vs cisplatin.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.